Monte Rosa Therapeutics, Inc.

Listed Company

GLUECIK 0001826457NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-38.60M

Total Assets

$448.66M

Equity

$233.06M

Shares Out

84.48M

Op. Cash Flow

$-22.80M

GLUE$24.56+316.89% · past yearDBEQ Basic

Daily closing prices

Business

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders (MGDs), small-molecule drugs that induce targeted protein degradation using the body's natural proteasome machinery. The company's QuEEN proprietary discovery platform identifies and designs MGDs against therapeutically relevant proteins considered undruggable by conventional approaches, with applications across immunology, inflammation, cardiovascular disease, and oncology. Current clinical programs include MRT-6160 (VAV1-directed MGD licensed to Novartis for immune-mediated diseases), MRT-8102 (NEK7-directed MGD for NLRP3-driven inflammatory diseases), and MRT-2359 (GSPT1-directed MGD for metastatic castration-resistant prostate cancer), supported by collaborations with Roche and Novartis and a library of over 75,000 rationally designed MGD molecules.

Summary from 10-K filed 2026-03-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue	124	76	0	—	—
Research and development	142	122	111	85	57
General and administrative	36	35	32	27	16
Total operating expenses	178	157	143	112	73
Loss from operations	−54	−81	−143	−112	−73
Interest income	13	11	9	4	46,000
Foreign currency exchange gain, net	1	416,000	−930,000	10,000	−162,000
Gain on disposal of fixed assets	59,000	0	24,000	109,000	0
Total other income	14	11	8	4	−1
Net loss before income taxes	−40	−70	−135	−109	—
Income tax benefit (provision)	1	−3	−338,000	0	—
Net loss	−39	−73	−135	−109	−74
Net loss per share attributable to common stockholders - basic	−0.46	−0.98	−2.63	−2.3	−2.96
Net loss per share attributable to common stockholders - diluted	−0.46	−0.98	−2.63	−2.3	−2.96
Weighted-average number of common shares used in computing net loss per share - basic	83	74	51	47	25
Weighted-average number of common shares used in computing net loss per share - diluted	83	74	51	47	25
Provision for pension benefit obligation	−518,000	−802,000	−1	718,000	−965,000
Unrealized gain on available-for-sale securities	47,000	170,000	397,000	−449,000	0
Comprehensive loss	−39	−73	−136	−108	−75

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	130	224	128	55	346
Marketable securities	247	148	104	208	0
Collaboration receivable	7	0	—	—	—
Other receivables	5	173,000	505,000	8	0
Prepaid expenses and other current assets	4	5	3	4	3
Total current assets	393	377	236	276	349
Property and equipment, net	26	29	34	27	12
Operating lease right-of-use assets	24	27	29	35	7
Restricted cash	5	5	5	4	5
Other long-term assets	148,000	115,000	352,000	278,000	0
Total assets	449	439	304	342	366
Accounts payable	4	17	11	8	7
Accrued expenses and other current liabilities	27	19	15	15	10
Current deferred revenue	30	117	18	0	—
Current portion of operating lease liability	4	4	3	3	0
Total current liabilities	64	157	47	26	17
Deferred revenue, net of current	111	16	32	0	—
Defined benefit plan liability	5	4	3	2	2
Operating lease liability, net of current	35	39	43	44	0
Total liabilities	216	216	125	71	19
Commitments and contingencies (Note 8)	—	—	—	—	—
Preferred stock, $0.0001 par value, 10,000,000 shares authorized	0	0	0	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized, 61,790,239 and 61,507,446 shares issued and outstanding as of December 31, 2025 and 2024, respectively	7,000	6,000	5,000	5,000	5,000
Additional paid-in capital	714	665	548	504	472
Accumulated other comprehensive loss	−4	−3	−3	−2	−2
Accumulated deficit	−477	−439	−366	−231	−122
Total stockholders' equity	233	223	179	271	348
Total liabilities and stockholders' equity	449	439	304	342	366

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−39	−73	−135	−109	−74
Stock-based compensation expense	19	18	17	12	5
Depreciation	8	8	6	4	2
Net accretion of discounts/premiums on marketable securities	−2	−3	−4	−2	0
Gain on disposal of property and equipment	−59,000	0	−24,000	−109,000	17,000
Collaboration receivable	−7	0	—	—	—
Other receivables	−4	332,000	2	−187,000	0
Prepaid expenses and other assets	604,000	−2	1	−2	−704,000
Accounts payable	−14	6	6	−744,000	−706,000
Accrued expenses and other current liabilities	8	4	4	1	7
Defined benefit plan liability	1	187,000	−188,000	74,000	1
Right-of-use assets and operating lease liabilities	−1	−1	10	−181,000	0
Deferred revenue	8	83	50	0	—
Net cash (used in) provided by operating activities	−23	42	−44	−92	−59
Purchases of property and equipment	−5	−4	−19	−13	−10
Purchases of marketable securities	−377	−230	−103	−384	0
Proceeds from maturities of marketable securities	280	190	165	178	—
Net cash used in investing activities	−102	−44	89	−219	−10
Proceeds from underwritten public offering, net of underwriter's discount of $3,000	0	47	0	—	—
Proceeds from issuance of pre-funded warrants	0	50	25	0	—
Payment of common stock and pre-funded warrant issuance costs	−357,000	−641,000	−116,000	−364,000	—
Proceeds from exercise of employee stock options	6	1	2	439,000	149,000
Proceeds from employee stock purchase plan	735,000	527,000	—	—	—
Net cash provided by financing activities	30	99	27	20	378
Net (decrease) increase in cash, cash equivalents and restricted cash	−94	96	72	−291	309
Purchases of property and equipment in accounts payable and accrued expenses	149,000	50,000	237,000	6	656,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Monte Rosa Therapeutics, Inc.'s CIK number?

Monte Rosa Therapeutics, Inc.'s SEC CIK number is 0001826457 (1826457). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Monte Rosa Therapeutics, Inc.'s SEC filings?

All of Monte Rosa Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Monte Rosa Therapeutics, Inc. last report earnings?

Monte Rosa Therapeutics, Inc. (GLUE) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-210298). This is Monte Rosa Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Monte Rosa Therapeutics, Inc.'s most recent earnings 8-K?

Monte Rosa Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-210298. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Monte Rosa Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →